Editas Medicine names James Mullen as chairman

Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.

Mullen has over 30 years’ experience leading biotechnology and pharmaceutical organisations on a global scale.

Previously, Mullen has served as chief executive officer of Patheon, a pharmaceutical development and manufacturing services provider, until its acquisition by Thermo Fisher Scientific last year.

Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.

Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome his as chairman of the board.

“Jim’s extensive experience in driving excellence across R&D, commercialisation, manufacturing, business development and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.”

In addition, the company announced that Alexis Borisy and John Mendlein stepped down from the board.